137 related articles for article (PubMed ID: 11810130)
1. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects.
de Jonge E; Levi M; Büller HR; Berends F; Kesecioglu J
Intensive Care Med; 2001 Nov; 27(11):1825-9. PubMed ID: 11810130
[TBL] [Abstract][Full Text] [Related]
2. Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial.
Schramko AA; Suojaranta-Ylinen RT; Kuitunen AH; Kukkonen SI; Niemi TT
Anesth Analg; 2009 Jan; 108(1):30-6. PubMed ID: 19095827
[TBL] [Abstract][Full Text] [Related]
3. [Changes in blood coagulation in treatment with hydroxyethyl starch].
Sefrin P; Rauch S; Zieglmeyer C
Anaesthesiol Reanim; 1998; 23(6):149-56. PubMed ID: 10036794
[TBL] [Abstract][Full Text] [Related]
4. Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects.
de Jonge E; Levi M; Berends F; van der Ende AE; ten Cate JW; Stoutenbeek CP
Thromb Haemost; 1998 Feb; 79(2):286-90. PubMed ID: 9493577
[TBL] [Abstract][Full Text] [Related]
5. Oncotic, hemodilutional, and hemostatic effects of isotonic saline and hydroxyethyl starch solutions in clinically normal ponies.
Jones PA; Tomasic M; Gentry PA
Am J Vet Res; 1997 May; 58(5):541-8. PubMed ID: 9140565
[TBL] [Abstract][Full Text] [Related]
6. Increased haemorrhagic risk after repeated infusion of highly substituted medium molecular weight hydroxyethyl starch.
Treib J; Haass A; Pindur G; Grauer MT; Jung F; Wenzel E; Schimrigk K
Arzneimittelforschung; 1997 Jan; 47(1):18-22. PubMed ID: 9037438
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
8. [The maximum safe dosage of the low molecular weight hydroxyethyl starch, HESPANDAR (HES), estimated from HES induced changes in coagulation parameters and clinical bleeding].
Saito Y; Uchida K; Yamamoto H; Ichiishi N; Matsushita F
Masui; 1999 Mar; 48(3):238-43. PubMed ID: 10214006
[TBL] [Abstract][Full Text] [Related]
9. [The accumulation of different substituted hydroxyethyl starches (HES) following repeated infusions in healthy volunteers].
Asskali F; Förster H
Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Sep; 34(9):537-41. PubMed ID: 10542895
[TBL] [Abstract][Full Text] [Related]
10. Effects of a hydroxyethylstarch solution on plasma colloid osmotic pressure in acutely ill patients.
Mbaba Mena J; De Backer D; Vincent JL
Acta Anaesthesiol Belg; 2000; 51(1):39-42. PubMed ID: 10806521
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
[TBL] [Abstract][Full Text] [Related]
12. The effect of 6% hydroxyethyl starch and desmopressin infusion on von Willebrand factor: ristocetin cofactor activity.
Lazarchick J; Conroy JM
Ann Clin Lab Sci; 1995; 25(4):306-9. PubMed ID: 7545380
[TBL] [Abstract][Full Text] [Related]
13. Coagulation disorders caused by hydroxyethyl starch.
Treib J; Haass A; Pindur G
Thromb Haemost; 1997 Sep; 78(3):974-83. PubMed ID: 9308738
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 10% HES 130/0.4 versus 10% HES 200/0.5 for plasma volume expansion in cardiac surgery patients.
Ertmer C; Wulf H; Van Aken H; Friederich P; Mahl C; Bepperling F; Westphal M; Gogarten W
Minerva Med; 2012 Apr; 103(2):111-22. PubMed ID: 22513516
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effect of hypertonic hydroxyethyl starch and mannitol on the intraocular pressure in healthy normotensive dogs and the effect of hypertonic hydroxyethyl starch on the intraocular pressure in dogs with primary glaucoma.
Volopich S; Mosing M; Auer U; Nell B
Vet Ophthalmol; 2006; 9(4):239-44. PubMed ID: 16771759
[TBL] [Abstract][Full Text] [Related]
16. [Decrease of thrombocyte volume after several days infusion of highly substituted medium molecular weight hydroxyethyl starch (HAES 200/0.62)].
Treib J; Haass A; Pindur G; Grauer MT; Wenzel E; Schimrigk K
Wien Klin Wochenschr; 1996; 108(1):20-3. PubMed ID: 8677658
[TBL] [Abstract][Full Text] [Related]
17. [Thrombelastographic coagulation analysis following in vitro and in vivo haemodilution with hydroxyethyl starch (HES)].
Asskali F; Lehmann G; Förster H
Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 May; 37(5):258-66. PubMed ID: 12015682
[TBL] [Abstract][Full Text] [Related]
18. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials.
Kozek-Langenecker SA; Jungheinrich C; Sauermann W; Van der Linden P
Anesth Analg; 2008 Aug; 107(2):382-90. PubMed ID: 18633012
[TBL] [Abstract][Full Text] [Related]
19. Effects of acute hypervolemic fluid infusion of hydroxyethyl starch and gelatin on hemostasis and possible mechanisms.
Jin SL; Yu BW
Clin Appl Thromb Hemost; 2010 Feb; 16(1):91-8. PubMed ID: 19825916
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic effects of 6% and 10% hydroxyethyl starch solutions versus 4% albumin solution in septic patients.
Friedman G; Jankowski S; Shahla M; Gomez J; Vincent JL
J Clin Anesth; 2008 Nov; 20(7):528-33. PubMed ID: 19019650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
